Vicore selects new ATRAG as next Drug Candidate
· C103, an angiotensin II type 2 receptor (AT2R) agonist (ATRAG), has been selected as Drug Candidate · The compound has a very high selectivity for the AT2R over the AT1R · A phase 1 trial is expected to start in H2-2023 Gothenburg, October 12, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces that the compound C103 has been selected as the company’s third ATRAG drug candidate to move forward into toxicology studies and thereafter a phase 1 trial. In preclinical testing, C103 has shown